Top Markets
Coin of the day
ObsEva S.A. ObsEva S.A.

ObsEva S.A.

OBSN
Classifica tra le azioni #40302
ObsEva S.A. is a biopharmaceutical company focused on developing and... ObsEva S.A. is a biopharmaceutical company focused on developing and commercializing groundbreaking therapies for women facing challenges in reproductive health and pregnancy. Its product pipeline includes Linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist currently in Phase III clinical trials. Linzagolix is being evaluated for its efficacy in treating pain associated with endometriosis and heavy menstrual bleeding linked to uterine fibroids in pre-menopausal women. The firm is also progressing with Ebopiprant, an oral and selective prostaglandin F2a (PGF2a) receptor antagonist, which is in Phase II clinical trials as a once-daily treatment for preterm labor occurring between 24 and 34 weeks of gestational age. Additionally, ObsEva is developing Nolasiban, an oral oxytocin receptor antagonist in Phase I clinical trials, aimed at enhancing clinical pregnancy and live birth rates for women undergoing in vitro fertilization. ObsEva S.A. was founded in 2012 and maintains its headquarters in Geneva, Switzerland.
Prezzo delle azioni
$0.00156067
Ultima sincronizzazione: 2024-05-03
Capitalizzazione di mercato
$182.87K
Variazione (1 giorno)
-72.69%
Variazione (1 anno)
0.00%
Paese
CH
Scambia ObsEva S.A. (OBSN)

Categoria

Storico del rendimento da dividendi per ObsEva S.A. (OBSN)
Il rendimento da dividendi (TTM) di ObsEva S.A. (simbolo azionario: OBSN) al 2026 è: 0
Rendimento medio negli ultimi 5 anni: 0.00%
Storico del rendimento da dividendi per ObsEva S.A. (OBSN) da 2026 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
Anno Rendimento da dividendi Cambia
Non abbastanza dati per le date fornite.
Rendimenti da dividendi (TTM) di aziende simili o concorrenti
Azienda Rendimento da dividendi Il paese
0.00%
US
0.00%
NL
0.00%
CH
0.00%
KR
0.65%
BE